Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.

Lancet
Renato D LopesACTION Coalition COVID-19 Brazil IV Investigators

Abstract

COVID-19 is associated with a prothrombotic state leading to adverse clinical outcomes. Whether therapeutic anticoagulation improves outcomes in patients hospitalised with COVID-19 is unknown. We aimed to compare the efficacy and safety of therapeutic versus prophylactic anticoagulation in this population. We did a pragmatic, open-label (with blinded adjudication), multicentre, randomised, controlled trial, at 31 sites in Brazil. Patients (aged ≥18 years) hospitalised with COVID-19 and elevated D-dimer concentration, and who had COVID-19 symptoms for up to 14 days before randomisation, were randomly assigned (1:1) to receive either therapeutic or prophylactic anticoagulation. Therapeutic anticoagulation was in-hospital oral rivaroxaban (20 mg or 15 mg daily) for stable patients, or initial subcutaneous enoxaparin (1 mg/kg twice per day) or intravenous unfractionated heparin (to achieve a 0·3-0·7 IU/mL anti-Xa concentration) for clinically unstable patients, followed by rivaroxaban to day 30. Prophylactic anticoagulation was standard in-hospital enoxaparin or unfractionated heparin. The primary efficacy outcome was a hierarchical analysis of time to death, duration of hospitalisation, or duration of supplemental oxygen to day 30...Continue Reading

References

Aug 13, 2011·The New England Journal of Medicine·Manesh R PatelUNKNOWN ROCKET AF Investigators
Aug 29, 2017·The New England Journal of Medicine·John W EikelboomUNKNOWN COMPASS Investigators
Nov 28, 2017·Journal of Biopharmaceutical Statistics·Gaohong DongMarc Vandemeulebroecke
Aug 28, 2018·The New England Journal of Medicine·Alex C SpyropoulosUNKNOWN MARINER Investigators
May 22, 2020·The New England Journal of Medicine·Maximilian AckermannDanny Jonigk
May 28, 2020·Journal of Thrombosis and Haemostasis : JTH·Alex C SpyropoulosUNKNOWN Subcommittee on Perioperative, Critical Care Thrombosis, Haemostasis of the Scientific, Standardization Committee of the Int
May 30, 2020·Critical Care Medicine·Toshiaki IbaJecko Thachil
Jun 27, 2020·Journal of the American College of Cardiology·Alex C SpyropoulosGary E Raskob
Jul 25, 2020·The New England Journal of Medicine·Alexandre B CavalcantiUNKNOWN Coalition Covid-19 Brazil I Investigators
Aug 1, 2020·Journal of the American College of Cardiology·Alexander C FanaroffRenato D Lopes
Aug 28, 2020·EBioMedicine·Baranca BuijsersJohan van der Vlag
Aug 30, 2020·Journal of the American College of Cardiology·Girish N NadkarniValentin Fuster
Oct 13, 2020·TH Open : Companion Journal to Thrombosis and Haemostasis·Galit H FrydmanGregory Piazza
Oct 17, 2020·Journal of the American College of Cardiology·Renato D Lopes, Alexander C Fanaroff
Nov 17, 2020·The New England Journal of Medicine·Helio P GuimarãesUNKNOWN RIVER Trial Investigators

❮ Previous
Next ❯

Citations

Jun 14, 2021·Lancet·Jeffrey S Berger, Jean Marie Connors
Jun 23, 2021·European Heart Journal. Cardiovascular Pharmacotherapy·Husam M SalahMarat Fudim
Jul 14, 2021·European Heart Journal·Noel Chan, John Eikelboom
Jul 18, 2021·Journal of Thrombosis and Haemostasis : JTH·Dawn SwanJecko Thachil
Jul 31, 2021·Infectious Diseases and Therapy·Matteo BassettiUNKNOWN Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)
Aug 29, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Andrea SpiniLuigia Trabace
Aug 30, 2021·Trends in Cardiovascular Medicine·Toshiaki Iba, Jerrold H Levy
Sep 20, 2021·Journal of Thrombosis and Haemostasis : JTH·Azita H TalasazBehnood Bikdeli
Oct 8, 2021·JAMA Internal Medicine·Lana Wahid, Thomas L Ortel
Oct 12, 2021·JAMA : the Journal of the American Medical Association·Otavio Berwanger
Oct 16, 2021·Frontiers in Public Health·Chenyang ZhangGuosheng Yin
Oct 12, 2021·JAMA : the Journal of the American Medical Association·Jean M ConnorsUNKNOWN ACTIV-4B Investigators
Sep 16, 2021·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jintanat AnanworanichPenny Heaton
Nov 4, 2021·Environmental Microbiology·Harald Brüssow
Nov 12, 2021·Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences·Pooria AsiliBagher Larijani
Nov 16, 2021·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·Brit Long, Michael Gottlieb
Nov 23, 2021·Hospital Practice·Bharat NarasimhanWilbert S Aronow

❮ Previous
Next ❯

Software Mentioned

R
ACTION

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.